Is bone marrow biopsy obligatory in all patients with non-Hodgkin's lymphoma?

被引：6

作者：

Bairey, Osnat ^{[1
]}

Shpilberg, Ofer ^{[1
]}

机构：

[1] Rabin Med Ctr, Inst Hematol, IL-49100 Petah Tiqwa, Israel

来源：

ACTA HAEMATOLOGICA | 2007年 / 118卷 / 01期

关键词：

bone-marrow biopsy; non-Hodgkin's lymphoma; aggressive lymphoma; indolent lymphoma; stage; extranodal; International Prognostic Index;

D O I：

10.1159/000102589

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Bone marrow biopsy (BMB) is recommended as a part of the workup diagnosis in all patients with non-Hodgkin's lymphoma (NHL). This is an invasive procedure that is mostly stressful for the patient and very rarely is associated with severe bleeding. We suggest that the clinician needs to weigh up the potential benefit of this procedure in each case in terms of changing therapeutic approach and prognosis. We think BMB is not mandatory in every patient with NHL and suggest recommendations for which patients we should continue to perform this procedure on. Copyright (c) 2007 S. Karger AG, Basel.

引用

页码：61 / 64

页数：4

共 28 条

[1]

ANDERSON T, 1980, CANCER, V50, P2699

[2]

Defining the stages of aggressive non-Hodgkin's lymphoma - A work in progress [J].

Armitage, JO .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (12) :1250-1252

[3]

Bain BJ, 2006, HAEMATOLOGICA, V91, P1293

[4]

A response to 'Emergency physicians are not anaesthetists' [J].

Baines, D .

ANAESTHESIA, 2003, 58 (04) :406-406

[5]

ASSESSMENT OF BONE-MARROW HISTOLOGY IN THE MALIGNANT-LYMPHOMAS (NON-HODGKINS) - CORRELATION WITH CLINICAL FACTORS FOR DIAGNOSIS, PROGNOSIS, CLASSIFICATION AND STAGING [J].

BARTL, R ;

FRISCH, B ;

BURKHARDT, R ;

KETTNER, G ;

MAHL, G ;

FATEHMOGHADAM, A ;

SUND, M .

BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (04) :511-530

[6]

Primary CNS lymphoma [J].

Batchelor, T ;

Loeffler, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (08) :1281-1288

[7]

For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? [J].

Bos, GMJ ;

van Putten, WLJ ;

van der Holt, B ;

van den Bent, M ;

Verdonck, LF ;

Hagenbeek, A .

ANNALS OF ONCOLOGY, 1998, 9 (02) :191-194

[8]

CNS prophylaxis and treatment in non-Hodgkin's lymphoma: Variation in practice and lessons from the literature [J].

Buckstein, R ;

Lim, W ;

Franssen, E ;

Imrie, KL .

LEUKEMIA & LYMPHOMA, 2003, 44 (06) :955-962

[9]

Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[10]

BONE-MARROW INVOLVEMENT BY NON-HODGKINS-LYMPHOMA - THE CLINICAL-SIGNIFICANCE OF MORPHOLOGICAL DISCORDANCE BETWEEN THE LYMPH-NODE AND BONE-MARROW [J].

CONLAN, MG ;

BAST, M ;

ARMITAGE, JO ;

WEISENBURGER, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1163-1172

← 1 2 3 →